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Editor,
I read with interest the article byLim et al. (2010). In this prospec-
tive study, the authors evidenced that
intravitreal bevacizumab alone has
similar efﬁcacy and safety to bev-
acizumab plus photodynamic therapy
(PDT) for the treatment of patients
with neovascular age-related macular
degeneration (AMD) and polypoidal
choroidal vasculopathy (PCV) at 12-
month follow-up. The authors con-
cluded that the addition of PDT did
not assist in reducing the required total
number of bevacizumab injections.
In their study, the authors did not
differ between the three recognized
forms of exudative AMD, which are
the classic form, the occult form, and
retinal angiomatous proliferation
(RAP). On the other hand, in their
series, a pigment epithelial detachment
(PED) was present in 22 ⁄ 31 (71%) of
eyes with AMD.
We know that PED is generally
because of sub-RPE neovasculariza-
tion in occult AMD (Gass 1997) or in
advanced stages of retinal angioma-
tous proliferation (Yannuzzi et al.
2001). The presence of a PED has
been shown to be almost constant in
occult AMD (Coscas et al. 2007).
Considering the high prevalence of
PED in the study by Lim et al., occult
types of AMD and advanced stages of
RAP are likely to be present in their
population.
Given that the lack of efﬁcacy of
PDT with verteporﬁn has been con-
ﬁrmed in occult CNV lesions (Kaiser
2009) and in patients with advanced
stages of RAP (Boscia et al. 2006),
the safety and efﬁcacy of VEGF
inhibitors has been shown in occult
types of neovascular AMD (Costagli-
ola et al. 2009) and RAP (Hemeida
et al. 2010). I would like to know the
opinion of the authors on the types of
exudative AMD to be treated with in-
travitreal bevacizumab in combination
with photodynamic therapy.
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